Abstract:Graves’ disease is always accompanied by thyroid-associated ophthalmopathy (TAO), and both of them shared the same pathophysiological characteristics, as it has been proved that thyroid-stimulating hormone receptor (TSHR) plays an essential role not only in the pathogenesis of Graves’ disease but also in that of TAO. TSHR expresses on orbital fibroblasts in the procedure of TAO, in which many factors such as cellular and humeral immunity, thyrotropin stimulating immunoglobulin (TSI), thyroid-stimulating hormone (TSH), platelet derived growth factor (PDGF) and other thyroid antibodies synergistically initiate the disease via TSHR. The activation of helper T cells recognizing TSHR peptides and ligation of TSHR by TRAb lead to the secretion of inflammatory cytokines and chemokines, and enhanced hyaluronic acid (HA) production and adipogenesis. The resulting connective tissue remodeling results in varying degrees extraocular muscle enlargement and orbital fat expansion. In addition to TSHR, orbital fibroblasts from patients with TAO express high levels of insulin-like growth factors-1 receptor (IGF-1R). Stimulatory autoantibodies direct against the insulin-like growth factor-1 receptor have been proposed to contribute to orbital fibroblast activation in TAO. (Int Rev Ophthalmol, 2019, 43: 47-52) Key words: Graves’ ophthalmopathy/pathogenesis

Research progression on CD40-CD40L costimulatory pathway in thyroid-associated ophthal mopathy

Research advancement on immunopathogenesis of thyroid-associated ophthalmopathy

The Involvement of T Cell Pathogenesis in Thyroid-Associated Ophthalmopathy

Research progress on inflammatory factors of thyroid-associated ophthalmopathy

Research Progress of Thyroid-associated Ophthalmopathy and Autoantigen

Thyroid-associated ophthalmopathy and ferroptosis: a review of pathological mechanisms and therapeutic strategies

The importance of basic research and drug development for thyroid-associated ophthalmopathy

[Research status of potential therapeutic targets for thyroid-associated ophthalmopathy]

Adcances on immunologic pathogenesis of thyroid-associated ophthalmopathy

Progress and Review in Thyroid-associated Ophthalmopathy

Thyroid-associated ophthalmopathy: cu-rrent concepts regarding etiopathogenesis and management

Comprehensive analysis of key genes and pathways for biological and clinical implications in thyroid-associated ophthalmopathy

Epigenetics effect on pathogenesis of thyroid-associated ophthalmopathy.

Current Status and Research Progress in the Conservative Treatment of Thyroid -Associated Ophthalmopathy

The research progress of the role of orbital preadipocytes in thyroid-associated ophthalmopathy

Cytokines in Thyroid-Associated Ophthalmopathy

Single-cell BCR and transcriptome analysis reveals peripheral immune signatures in patients with thyroid-associated ophthalmopathy

Looking Beyond Th17 Cells: A Role for Th17.1 Cells in Thyroid-associated Ophthalmopathy?

Immune mechanisms and treatment of thyroid associated ophthalmopathy

The Stepwise Establishment of Standardized Treatment for the Thyroid Eye Disease

Immune checkpoints: new insights into the pathogenesis of thyroid eye disease